Mativ Holdings (MATV) Earnings Date & Reports

Key Takeaways

• Mativ Holdings (MATV) will report second quarter 2026 financial results on August 5, 2026, after the market closes, followed by a conference call on August 6.
• Wall Street consensus points to adjusted earnings per share (EPS) of $0.28 on revenue of approximately $508.5 million, representing a year-over-year EPS decline from $0.33 in Q2 2025.
• Management has guided for Q2 adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) to decline by a mid-single-digit percentage compared to the prior-year period, primarily due to healthcare segment destocking and a temporary facility outage.
• Input cost inflation estimates for full-year 2026 have been revised sharply higher to $40–$50 million, up from an initial $20–$25 million, driven by polymer and resin price increases tied to Middle East conflict dynamics.
• The company enters this report with momentum from Q1 2026, when adjusted EBITDA rose 28% year-over-year and margins reached their highest level since the 2022 merger.

Earnings Context and Why It Matters

Mativ Holdings, a specialty materials manufacturer formed through the 2022 merger of Schweitzer-Mauduit International and Neenah, is navigating a complex operating environment. The company serves diverse end markets — including filtration, healthcare, transportation, and packaging — through its two segments: Filtration & Advanced Materials (FAM) and Sustainable & Adhesive Solutions (SAS). This Q2 2026 report lands at a pivotal moment. After delivering its strongest Q1 margins since the merger, Mativ now faces a sharp upward revision in raw material costs and pockets of demand softness, particularly in healthcare. Investors will be looking for evidence that pricing actions and cost-saving initiatives can preserve the margin gains achieved in recent quarters. With the stock trading near $8.68 and a consensus analyst price target significantly higher, the market's reaction will hinge on whether Mativ can demonstrate resilience against these headwinds.

Earnings Expectations

Analyst consensus for Q2 2026 stands at adjusted EPS of $0.28 on revenue of roughly $508.5 million, according to data compiled by Finviz and other financial data providers. This compares to Q2 2025 reported adjusted EPS of $0.33 and revenue of $525.4 million. On a GAAP (Generally Accepted Accounting Principles) basis, the consensus estimate is just $0.01 per share, reflecting ongoing restructuring and non-cash charges that have historically created a wide gap between adjusted and GAAP results.

Management set expectations during the Q1 2026 earnings call in May, guiding for Q2 adjusted EBITDA to decline by a mid-single-digit percentage relative to the prior-year period. The primary headwinds cited were near-term demand weakness in healthcare — driven by customer inventory destocking and a temporary production outage — and the escalating cost of key raw materials. Partially offsetting these pressures, the company pointed to growth in its filtration, films, and finished tapes product categories.

Mativ has a track record of exceeding adjusted EPS estimates, having done so in six of the last eight quarters. However, revenue has been less predictable, beating consensus only three times in the same span. The Q1 2026 report illustrated this dynamic: adjusted EPS of $0.06 beat the $0.02 consensus by a wide margin, yet revenue of approximately $480 million fell short of the $486.9 million estimate. The Q2 report will test whether the company can deliver another bottom-line surprise while revenue remains under pressure.

AI Screener

For investors looking to identify stocks with similar earnings momentum or technical characteristics ahead of key events, Tickeron's AI Screener offers a powerful solution. The AI Screener is an artificial intelligence-driven stock and ETF (exchange-traded fund) discovery tool that enables traders and investors to filter thousands of securities using customizable criteria, including industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-powered trading signals. Whether scanning for breakout candidates, trend-following opportunities, or value plays within the specialty materials sector, the AI Screener streamlines the research process and helps surface actionable ideas more efficiently than manual screening methods. Explore the AI Screener to see how data-driven filtering can sharpen your market analysis.

Market Reaction and Investor Sentiment

Heading into the August 5 release, sentiment around Mativ remains cautious. The stock has traded within a wide 52-week range of $6.17 to $15.48 and recently changed hands around $8.68, reflecting a market capitalization of approximately $450 million. The stock's forward dividend yield of roughly 5% and a trailing price-to-earnings ratio near 6 have attracted income-oriented and value-focused investors, but broader analyst conviction is mixed — recent ratings have ranged from hold to sell, with limited active coverage from Wall Street.

Key risk factors weighing on sentiment include the magnitude of input cost inflation, uncertainty around the pace of healthcare destocking, and whether pricing actions implemented in January and March 2026 can fully offset rising polymer and resin costs. On the positive side, the company's April 2026 debt refinancing — which extended maturities to 2031 and 2033 and simplified the capital structure — has reduced near-term balance sheet risk and improved financial flexibility. How the market reacts will likely depend on whether Mativ reaffirms or adjusts its full-year outlook and whether adjusted EBITDA margins hold above the 9.9% level achieved in Q1.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, several interconnected themes will shape Mativ's trajectory through the second half of 2026 and into 2027.

Input cost trajectory: The revision of full-year raw material inflation from $20–$25 million to $40–$50 million represents a significant swing. Polymer and resin prices have been pushed higher by geopolitical tensions in the Middle East, and the key question is whether these costs have peaked or will continue to escalate. Mativ has implemented incremental pricing actions, but the timing lag between cost increases and pricing realization will be a critical factor for margins in Q3 and Q4.

Healthcare recovery: The healthcare segment's destocking cycle and the temporary facility outage are, by management's description, near-term issues. Investors should monitor commentary on whether these headwinds are easing as anticipated and whether the segment returns to growth in the second half of the year.

Cost savings execution: Mativ is targeting $15–$20 million in cost savings for 2026, building on nearly $20 million realized in 2025 across SG&A (selling, general, and administrative expenses), operations, and procurement. Progress on this front is essential to protecting margins as input costs rise.

Balance sheet and cash flow: With net debt of approximately $954 million and net leverage of 4.1x at the end of Q1, deleveraging remains a priority. The company's target range of 2.5–3.5x net leverage is still some distance away. Free cash flow is expected to be heavily weighted toward Q2 and Q3 after a seasonal Q1 use of cash, and the pace of cash generation will directly influence the timeline for reaching leverage targets. Annual interest expense is forecast at approximately $76 million, making debt reduction a meaningful contributor to future earnings growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations